You know I felt that way the first time I read the PR.
Then I read it a second time and I read it as if Pasaca wrote it and I came away with a totally different vibe.
The most important thing to remember is before Pasaca can become a real part of the QMC equation AS needs to be raised.
Until that happens there is no Pasaca Capital take over (they are only a minority shareholder) and why I believe they are not mention directly in this PR.
And isn't the Pasaca ;loans and the 51% buyout agreement classified as a " fulfill certain obligations that we have to investors."?
How would a Pasaca backed CEO run a a cash starved company
- identify immediate profitable projects
- redirect resources from non profitable projects to profitable projects
- abandon, put on hold or sell unprofitable projects
- add essential employees and release non essential employees to those profitable projects "We intend to continue the expansion of our biotech staff and capabilities,"
The inclusion of Innova and Pasaca in the PR indirectly:
It appears by the products that they will be concentrating on, the Pasaca's 15 million dollar agreement is still in effect.
"POCT ...technology is intended to part of our immediate commercialization focus."
"The Company recognized early in the advent of Covid-19 that we could use our proprietary technologies to design and develop a more sensitive lateral flow test kit using our unique quantum dot technologies. Over the past several months, we have expanded our biotech team and collaborated with our material scientists. As a result, we have now developed a point of care test platform (POCT) that we believe is more sensitive than current technologies. We believe it will provide analytic sensitivity that can rival PCR and provide quantitative results when warranted. We are currently developing 1) LFTs (lateral flow test kits) for TBI (traumatic brain injury, aka concussions), 2) a multiplex test that detects Covid-19, Flu and RSV (Respiratory Syncytial Virus), and 3) a vaccine validator to thwart counterfeit vaccines and validate vaccine efficacy. This test kit technology uses a unique quantum dot as a signal amplifier and can give a visual test result indication using a low-cost UV light source or using our POCT reader to interface with a P.C. or a smartphone. This reader is designed to provide a binary readout indicating positive or negative and a quantitative result indicating the level of viral loading. We believe that this can be very valuable, particularly in viruses like Covid-19, where a current test cannot reliably identify low viral loading, which is often the case in asymptomatic individuals who are the most likely to spread the virus unknowingly."
That is what Pasaca was hiring them for wasn't it?
Quote:frankly I don't think they help in our current situation. We have been talking about the "what if's" and "the positives" for quite some time, only to end up revoked. If we do end up back on the market, I foresee massive dilution, no partnership, and a decrease in our investment. Now, I can be wrong in all of this, but this is what I personally think. We'll have to see what the Consent Solicitation shows.
Then I read it a second time and I read it as if Pasaca wrote it and I came away with a totally different vibe.
The most important thing to remember is before Pasaca can become a real part of the QMC equation AS needs to be raised.
Until that happens there is no Pasaca Capital take over (they are only a minority shareholder) and why I believe they are not mention directly in this PR.
And isn't the Pasaca ;loans and the 51% buyout agreement classified as a " fulfill certain obligations that we have to investors."?
How would a Pasaca backed CEO run a a cash starved company
- identify immediate profitable projects
- redirect resources from non profitable projects to profitable projects
- abandon, put on hold or sell unprofitable projects
- add essential employees and release non essential employees to those profitable projects "We intend to continue the expansion of our biotech staff and capabilities,"
The inclusion of Innova and Pasaca in the PR indirectly:
It appears by the products that they will be concentrating on, the Pasaca's 15 million dollar agreement is still in effect.
"POCT ...technology is intended to part of our immediate commercialization focus."
"The Company recognized early in the advent of Covid-19 that we could use our proprietary technologies to design and develop a more sensitive lateral flow test kit using our unique quantum dot technologies. Over the past several months, we have expanded our biotech team and collaborated with our material scientists. As a result, we have now developed a point of care test platform (POCT) that we believe is more sensitive than current technologies. We believe it will provide analytic sensitivity that can rival PCR and provide quantitative results when warranted. We are currently developing 1) LFTs (lateral flow test kits) for TBI (traumatic brain injury, aka concussions), 2) a multiplex test that detects Covid-19, Flu and RSV (Respiratory Syncytial Virus), and 3) a vaccine validator to thwart counterfeit vaccines and validate vaccine efficacy. This test kit technology uses a unique quantum dot as a signal amplifier and can give a visual test result indication using a low-cost UV light source or using our POCT reader to interface with a P.C. or a smartphone. This reader is designed to provide a binary readout indicating positive or negative and a quantitative result indicating the level of viral loading. We believe that this can be very valuable, particularly in viruses like Covid-19, where a current test cannot reliably identify low viral loading, which is often the case in asymptomatic individuals who are the most likely to spread the virus unknowingly."
That is what Pasaca was hiring them for wasn't it?
